AAPG

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Index	-	P/E	-	EPS (ttm)	-2.01	Insider Own	-	Shs Outstand	52.23M	Perf Week	-0.10%
Market Cap	3.75B	Forward P/E	47.27	EPS next Y	0.86	Insider Trans	-	Shs Float	-	Perf Month	-1.68%
Enterprise Value	3.76B	PEG	-	EPS next Q	-	Inst Own	0.09%	Short Float	-	Perf Quarter	26.36%
Income	-160.62M	P/S	69.44	EPS this Y	-97.50%	Inst Trans	-3.22%	Short Ratio	1.46	Perf Half Y	117.18%
Sales	54.07M	P/B	87.68	EPS next Y	158.73%	ROA	-37.67%	Short Interest	0.02M	Perf YTD	132.80%
Book/sh	0.46	P/C	16.19	EPS next 5Y	26.06%	ROE	-161.90%	52W High	48.45 -16.49%	Perf Year	-
Cash/sh	2.50	P/FCF	-	EPS past 3/5Y	26.85% 36.70%	ROIC	-74.33%	52W Low	16.50 145.21%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	215.77% 130.37%	Gross Margin	68.92%	Volatility	2.52% 2.69%	Perf 5Y	-
Dividend TTM	-	EV/Sales	69.61	EPS Y/Y TTM	-191.46%	Oper. Margin	-287.25%	ATR (14)	1.60	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.53	Sales Y/Y TTM	-56.78%	Profit Margin	-297.05%	RSI (14)	47.52	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.54	EPS Q/Q	-	SMA20	-5.43%	Beta	-	Target Price	47.00
Payout	-	Debt/Eq	2.58	Sales Q/Q	-	SMA50	-1.38%	Rel Volume	0.92	Prev Close	39.89
Employees	567	LT Debt/Eq	1.32	Earnings	Aug 20 AMC	SMA200	39.62%	Avg Volume	10.50K	Price	40.46
IPO	Jan 27, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	9,657	Change	1.43%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-25	Initiated	JP Morgan	Overweight

Sep-01-25 12:00PM	Ascentage Pharma Group International - Unsponsored ADR (AAPG) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Here's Why Ascentage Pharma Group International - Unsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-25-25 08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025 (GlobeNewswire) -9.23%
Aug-20-25 07:57PM	Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates (GlobeNewswire)
Aug-19-25 04:20PM	Ascentage Pharmas Lisaftoclax Gets FDA/EMA Clearance (Exec Edge)
07:30PM	Loading…
Aug-17-25 07:30PM	Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA (GlobeNewswire)
Aug-07-25 08:00AM	Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 (GlobeNewswire)
Aug-01-25 08:00AM	Ascentage Pharma to Participate in Evercore China Biotech Summit (GlobeNewswire)
Jul-23-25 08:00AM	Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025 (GlobeNewswire)
Jul-21-25 12:14AM	Ascentage Pharma Raises $192.3M Through Oversubscribed Offshore Share Placement (Insider Monkey)
Jul-17-25 04:30AM	Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement (GlobeNewswire)
Jul-14-25 11:12AM	Ascentage Pharma's Novel Cancer Drug Approved in China (Insider Monkey) -5.33%
10:35AM	Ascentage Pharma Announces Pricing of Top-Up Placement (GlobeNewswire)
05:23AM	Ascentage Pharma Announces Proposed Top-Up Placement (GlobeNewswire)
Jul-10-25 12:55PM	Ascentage Pharma Announces NMPA Approval for Blood Cancer Drug (Exec Edge)
09:30AM	Loading…
09:30AM	Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL (GlobeNewswire)
Jul-08-25 11:58AM	Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance (Exec Edge)
Jul-07-25 07:30PM	Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance (GlobeNewswire)
Jun-15-25 07:30PM	EHA 2025 Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL (GlobeNewswire)
Jun-09-25 07:30PM	Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress (GlobeNewswire) +5.29%
Jun-02-25 07:30PM	Live from ASCO 2025 Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors (GlobeNewswire) +10.03%
07:30PM	Live from ASCO 2025 Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report (GlobeNewswire)
May-22-25 08:15PM	Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 (GlobeNewswire)
May-11-25 05:20PM	Is Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now? (Insider Monkey)
Apr-28-25 07:00AM	Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax (GlobeNewswire)
Apr-23-25 07:00PM	Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin (GlobeNewswire) +10.65% +6.69%
Apr-21-25 06:10PM	Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines (Exec Edge) +12.97%
07:00AM	Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines (GlobeNewswire)
Apr-02-25 01:07PM	Stocks To Watch In Gloomy Market Including This Breakout IPO (Investor's Business Daily)
Mar-27-25 07:00AM	Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates (GlobeNewswire) +9.96%
07:00PM	Loading…
Mar-25-25 07:00PM	Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Mar-12-25 08:46AM	Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 (GlobeNewswire)
Mar-06-25 05:18PM	Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment (Exec Edge)
Mar-05-25 06:00PM	Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (GlobeNewswire)
Feb-07-25 08:24AM	Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares (GlobeNewswire)
Jan-28-25 04:01PM	Ascentage Pharma Announces Closing of U.S. Initial Public Offering (GlobeNewswire)

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Ascentage Pharma Group International ADR

Upgrade your FINVIZ experience